Iron Triangle Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Iron Triangle Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$34.9M	Buy	+76,910	New	+$33.2M	3.99%	11

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Iron Triangle Partners's VRTX Position: Q4 2025 in Review

Iron Triangle Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2025: 76,910 shares worth $34.9M. The stake represents 3.99% of the portfolio and ranks #11 among its holdings.

1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Iron Triangle Partners held 76,910 shares of Vertex Pharmaceuticals worth $34.9M as of Q4 2025.
Vertex Pharmaceuticals was a new Iron Triangle Partners position in Q4 2025.
Vertex Pharmaceuticals made up 3.99% of Iron Triangle Partners's portfolio in Q4 2025, its #11 holding.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.